<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400839</url>
  </required_header>
  <id_info>
    <org_study_id>2.143.496</org_study_id>
    <nct_id>NCT03400839</nct_id>
  </id_info>
  <brief_title>Best Clinical Endpoints That Likely Induce Worse Prognosis in Interstitial Lung Diseases</brief_title>
  <acronym>BELIEVE-ILD</acronym>
  <official_title>Investigation of the Impact of Clinical Outcomes on Disease Progression and Prognosis in Patients With Interstitial Lung Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Estadual de Londrina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidade Norte do Paraná</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Estadual de Londrina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective cohort study will investigate whether progression of the interstitial lung
      diseases is related to specific clinical endpoints and their changes over time. Longitudinal
      data of patients will be compared to an age-matched control group during a follow-up of at
      least two years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of daily steps over time</measure>
    <time_frame>from date of inclusion until the date of study completion or until the documented date of death from any cause, whichever came first, up to 48 months</time_frame>
    <description>Changes in daily steps (measured using an activity monitor) at every 6-month interval until study completion or end of participation in the study.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>Patients with ILD</arm_group_label>
    <description>Patients with a medical diagnosis of interstitial lung disease.
Patients will be submitted to the assessment of:
Daily physical activity levels;
6-minute walk test;
Cardiopulmonary exercise testing;
Muscle Function;
Lung Function;
Body composition;
HRQoL - SGRQ-I;
HRQoL - SF36;
Anxiety and depression;
Symptoms - mMRC
Symptoms - UCSD/SOBQ;
Sleep quality;
Sleepiness;
Inflammatory markers and oxidative stress.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Age-matched peers without lung diseases.
Participants will be submitted to the assessment of:
Daily physical activity levels;
6-minute walk test;
Cardiopulmonary exercise testing;
Muscle Function;
Lung Function;
Body composition;
HRQoL - SF36;
Anxiety and depression;
Sleep quality;
Sleepiness;
Inflammatory markers and oxidative stress.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Daily physical activity levels</intervention_name>
    <description>Objectively measured physical activity using activity monitors.</description>
    <arm_group_label>Patients with ILD</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>6-minute walk test</intervention_name>
    <description>Assessment of functional exercise capacity.</description>
    <arm_group_label>Patients with ILD</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiopulmonary exercise testing</intervention_name>
    <description>Assessment of maximal exercise capacity.</description>
    <arm_group_label>Patients with ILD</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Muscle Function</intervention_name>
    <description>Assessment of muscle force, muscle endurance and muscle fatigability</description>
    <arm_group_label>Patients with ILD</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Lung Function</intervention_name>
    <description>Assessment of whole-body plethysmography and spirometry.</description>
    <arm_group_label>Patients with ILD</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Body composition</intervention_name>
    <description>Assessment of bioelectrical impedance.</description>
    <arm_group_label>Patients with ILD</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HRQoL - SGRQ-I</intervention_name>
    <description>Assessment of Health-related quality of life by the &quot;Saint-George Respiratory questionnaire (SGRQ-I)&quot;</description>
    <arm_group_label>Patients with ILD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Symptoms - UCSD/SOBQ</intervention_name>
    <description>Assessment of symptoms by the &quot;UCSD Short of breath questionnaire&quot;</description>
    <arm_group_label>Patients with ILD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HRQoL - SF36</intervention_name>
    <description>Assessment of Health-related quality of life by the &quot;SF-36 questionnaire&quot;</description>
    <arm_group_label>Patients with ILD</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Anxiety and depression</intervention_name>
    <description>Assessment of anxiety and depression by the &quot;Hospital Anxiety And Depression (HADS) Scale&quot;</description>
    <arm_group_label>Patients with ILD</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Symptoms - mMRC</intervention_name>
    <description>Assessment of symptoms by the &quot;modified Medical Research Council (mMRC) scale&quot;</description>
    <arm_group_label>Patients with ILD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sleep quality</intervention_name>
    <description>Assessment of sleep by the &quot;Pitsburg Sleep Quality Index (PSQI)&quot;</description>
    <arm_group_label>Patients with ILD</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sleepiness</intervention_name>
    <description>Assessment of sleepiness by the &quot;Epworth Sleepiness Scale&quot;</description>
    <arm_group_label>Patients with ILD</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Inflammatory markers and oxidative stress</intervention_name>
    <description>blood assessment of inflammatory markers: IL-2, IL-10, IL-6, IL-4 e IL-17A, TNF, Interferon-γ, CK and CRP.
Blood assessment of oxidative stress: TRAP, SH, SOD, CAT, PON 1, Gpx, MDA, NOx, FOX and AOPP.</description>
    <arm_group_label>Patients with ILD</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Clinical and biological data collected in the study may be used in other investigations upon
      participants written consent
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A non-probabilistic sample (invitation to volunteer) including participants from the urban
        region of Londrina, Brazil and surroundings.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with interstitial lung disease:

               -  Age between 40 and 75 years old upon inclusion;

               -  Diagnosis of interstitial lung disease;

               -  Clinical stability for at least 4 weeks prior to inclusion;

               -  Absence of any comorbidity that interferes with the performance of tests;

          2. Age-matched control group:

               -  Age between 40 and 75 years old upon inclusion;

               -  Absence of any comorbidity that interferes with the performance of tests;

        Exclusion Criteria (both groups):

          -  Participants that present severe or unstable cardiac disease identified during the
             cardiopulmonary exercise testing;

          -  Participants with cognitive deficit that interfere with any of the tests;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos A Camillo, PT, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Estadual de Londrina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos A Camillo, PT, PhD</last_name>
    <phone>+554333712490</phone>
    <email>carlos.a.camillo@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabio Pitta, PT, PhD</last_name>
    <phone>+554333712477</phone>
    <email>fabio.pitta@uol.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Estadual de Londrina</name>
      <address>
        <city>Londrina</city>
        <state>Paraná</state>
        <zip>86038-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos A Camillo, PT, PhD</last_name>
      <phone>+554333712490</phone>
      <email>carlos.a.camillo@outlook.com</email>
    </contact>
    <contact_backup>
      <last_name>Fabio Pitta, PT, PhD</last_name>
      <phone>+554333712477</phone>
      <email>fabio.pitta@uol.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Humberto Silva, PT, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wagner F Aguiar, PT, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcos Ribeiro, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabio Pitta, PT, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos A Camillo, PT, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interstitial Lung disease</keyword>
  <keyword>prognosis</keyword>
  <keyword>clinical endpoints</keyword>
  <keyword>association</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data collected may be used in other studies upon participants' written consent. However, it is not the intention of investigators to share the data publically (In exception of final results of the study after completion)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

